GlassScriptPhysician profile
Cathy Duong
NPI 1548032311
$1,650.64
in general payments reported to CMS, 2019-2025
17 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $35.04 · 2024: $1,456 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $94.99 · Consulting Fee: $30.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.27 |
| Education | $94.99 |
| Consulting Fee | $30.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $375.08 | 2023-2024 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $214.20 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $136.92 | 2024 | Cuvitru, Hyqvia, Takhzyro |
| Novartis Pharmaceuticals Corporation | $133.29 | 2024 | |
| Astellas Pharma US INC | $120.68 | 2025 | Xospata |
| Csl Behring | $119.25 | 2023-2024 | Haegarda, Hizentra |
| Pharming Healthcare, INC. | $113.18 | 2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Genzyme Corporation | $63.92 | 2024 | |
| Grifols USA, LLC | $49.89 | 2024 | Xembify |
| Genentech USA, INC. | $44.40 | 2024 | Xolair |
| Abbvie INC. | $38.99 | 2025 | |
| Biocryst US Sales Co., LLC | $31.71 | 2024 | Orladeyo |
| Adma Biomanufacturing LLC | $30.38 | 2024 | |
| Pfizer INC. | $29.97 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.95 | 2024 | Nucala |
| Alk-Abello, INC | $24.84 | 2024 | Grastek, Ragwitek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.